Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Proteome Sciences ( (GB:PRM) ) just unveiled an announcement.
Proteome Sciences has secured a significant contract with a US biopharmaceutical company to provide mass spectrometry services for a clinical trial, valued at over $1 million. This agreement, which utilizes their GCLP accreditation, is expected to be largely fulfilled within the current financial year and into 2026, demonstrating the company’s growing demand in the US and Europe for its specialized services.
More about Proteome Sciences
Proteome Sciences is a company in the biotechnology industry, specializing in mass spectrometry services. The company focuses on providing analytical services to the biopharmaceutical sector, with a market focus on clinical trials and drug performance monitoring.
YTD Price Performance: 32.06%
Average Trading Volume: 169,388
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £13.25M
For detailed information about PRM stock, go to TipRanks’ Stock Analysis page.
